The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up.
 
Andrea B. Apolo
No Relationships to Disclose
 
John Allan Ellerton
No Relationships to Disclose
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Manish Agrawal
No Relationships to Disclose
 
Michael S. Gordon
Stock and Other Ownership Interests - Caremission; WCCT Global
Consulting or Advisory Role - Castle Biosciences; Deciphera; RedHill Biopharma; TRACON Pharma
Research Funding - Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); BeiGene (Inst); BiolineRx (Inst); Calithera Biosciences (Inst); CanBas (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Hengrui Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); SynDevRx (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials
 
Raid Aljumaily
Consulting or Advisory Role - AstraZeneca; Regeneron
 
Carolyn D. Britten
Consulting or Advisory Role - Cleave Biosciences
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Halozyme (Inst); Incyte (Inst); Keystone Nano (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Plexxikon (Inst); RedHill Biopharma (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Five Prime Therapeutics
 
Luc Dirix
No Relationships to Disclose
 
Keun-Wook Lee
Research Funding - Array BioPharma (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst)
 
Matthew H. Taylor
Consulting or Advisory Role - ArQule; Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Eisai
 
Patrick Schoffski
Consulting or Advisory Role - Blueprint Medicines (Inst); Eisai (Inst); Ellipses Pharma (Inst); Epizyme (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Piqur (Inst); Plexxikon (Inst)
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Ding Wang
Consulting or Advisory Role - Merck
Travel, Accommodations, Expenses - Merck
 
Alain Ravaud
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Junyuan Xiong
Employment - EMD Serono
 
Galit Rosen
Employment - EMD Serono
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Merck (Inst); NantBioScience (Inst); Pfizer (Inst)
 
Manish R. Patel
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical